United Immunity, Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
United Immunity, Co., Ltd. - overview
Established
2017
Location
Tokyo, -, Japan
Primary Industry
Healthcare Specialists
About
Based in Tokyo, Japan, United Immunity, Co. , Ltd. specializes in innovative drug delivery systems, merging immunotherapy with nanoparticle technology to enhance therapeutic efficacy in treating various diseases, including cancer and autoimmune disorders. Founded in 2017 in Tokyo, Japan, United Immunity, Co.
, Ltd. focuses on developing advanced drug delivery systems. The company has completed 4 deals, with the most recent being a Series B funding round on September 11, 2023, raising JPY 823 million from investors including Saisei Ventures and The University of Tokyo Edge Capital Partners. Naozumi Harada is the founder, with a history of involvement in the biotechnology sector.
United Immunity Co. , Ltd. specializes in the development of innovative drug delivery systems that integrate immunotherapy and nanoparticle technology. Core products like Pullulan Nanoparticles (PNP) and Pullulan-Lipid Nanoparticles (P-LNP) are engineered to selectively deliver therapeutic agents to myeloid cells to enhance treatments for diseases such as cancer and autoimmune disorders.
The company targets pharmaceutical and research institutions across North America, Europe, and Asia. The revenue model of United Immunity is based on partnerships with pharmaceutical and biotech companies to develop and commercialize proprietary drug delivery systems. Through B2B transactions, the company generates revenue via licensing agreements and collaborations, involving milestone payments and royalties based on the success of the drugs delivered using their Myeloid Targeting Platform™. In September 2023, United Immunity, Co.
, Ltd. raised JPY 823 million in Series B funding, aimed at advancing the lead program (UI-101). The company plans to launch new drug delivery products and expand its presence in North America, Europe, and Asia through tailored solutions for improved therapeutic outcomes in the coming years.
Current Investors
Mitsubishi UFJ Capital, Axil Capital, University of Tokyo Edge Capital Partners
Primary Industry
Healthcare Specialists
Sub Industries
Oncology/Cancer Treatment
Website
www.unitedimmunity.co.jp
Verticals
Nanotechnology
Company Stage
Series B
Total Amount Raised
Subscriber access only
United Immunity, Co., Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.